bioMérieux ConnectionAn educational resource brought to you by bioMérieux, Inc.
An educational resource brought to you by bioMérieux, Inc.
As cases of COVID-19 are on the rise again in several places in the U.S., the need for effective treatment remains. Many potential COVID-19 treatments that could have an impact on our ability to fight the virus are currently being developed or tested in clinical trials.
In the United States, Group B Streptococcus (GBS) bacteria are a leading cause of meningitis and sepsis in a newborn’s first three months of life. The bacteria may be passed from pregnant women to their babies during delivery, because about one in every four pregnant women carry GBS bacteria in their body.
Without basic scientific research, we would not have the building blocks we need to come up with new diagnostics, treatments, or preventives.
The ability to combat the SARS-CoV-2 virus through accelerated advancements in diagnostics, treatment and vaccine development relies on understanding how the virus is transmitted between people and accurately tracking mutations. Whole genome sequencing and subsequent analysis can provide a wealth of data and contribute important insights to this effort.
Amid the spread of COVID-19, testing for SARS-COV-2, the virus...
Patients at the greatest risk for secondary infections, particularly infections...